Lataa...

Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90–100% of malignant mature B-lymphocyte lineage. The first Pha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Immunotherapy
Päätekijät: George, Binsah, Kantarjian, Hagop, Jabbour, Elias, Jain, Nitin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Future Medicine Ltd 2016
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5618942/
https://ncbi.nlm.nih.gov/pubmed/26780449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.15.108
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!